Accordingly, the TGF-β1 antagonists convert basal-like or HER2-positive tumor cells into epithelioid, non-proliferating and non-metastatic cells, which makes them candidates for targeted therapy in the TNBC cases (11). The gene discussed is ERBB2; the disease is neoplasm.